LENZ
Lenz Therapeutics Inc
NASDAQ · Pharmaceuticals
$14.22
+0.25 (+1.79%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 61.59M | 55.54M | 66.64M |
| Net Income | 19.38M | 14.59M | 22.25M |
| EPS | — | — | — |
| Profit Margin | 31.5% | 26.3% | 33.4% |
| Rev Growth | +17.7% | +18.8% | -7.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 192.21M | 201.78M | 216.87M |
| Total Equity | 194.79M | 170.45M | 172.69M |
| D/E Ratio | 0.99 | 1.18 | 1.26 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 32.48M | 26.94M | 31.76M |
| Free Cash Flow | 24.80M | 19.95M | 25.11M |